An Efficacy and Safety Study of Reslizumab Subcutaneous in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood Eosinophils
A Phase 3, 24-Week Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Reslizumab Subcutaneous Dosing (110 mg Every 4 Weeks) in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood Eosinophils
Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.
A PHASE3 clinical study on Asthma and Elevated Blood Eosinophils, this trial is completed. The trial is conducted by Teva Branded Pharmaceutical Products R&D, Inc. and has accumulated 12 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE3
▶ Show 7 earlier versions
-
May 2020 — Jan 2021 [monthly]
Completed PHASE3
-
Oct 2018 — May 2020 [monthly]
Completed PHASE3
-
Jun 2018 — Oct 2018 [monthly]
Completed PHASE3
-
Dec 2017 — Jun 2018 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Nov 2017 — Dec 2017 [monthly]
Active Not Recruiting PHASE3
-
Feb 2017 — Nov 2017 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Sep 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Teva Branded Pharmaceutical Products R&D, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .